領導致詞：
成都云克藥業有限責任公司前身為中國核動力研究設計院同位素應用研究所，是以研究核素治療藥物為主，帶動其他核技術診療產品研究的高科技創新型企業，在全國核素藥物服務領域，位列前三。我們將不斷提高綜合科研能力和技術水平，培植核心競爭力，推進科技、管理、體制和運行機制創新，培育獨具特色的云克藥業企業文化，以蓬勃向上的姿態，迎接挑戰，向國際一流核技術服務公司邁進，為我國核素診療事業的發展勇攀高峰，再創輝煌。在此，我代表云克藥業全體職工，向所有關心和支持我公司工作的各級領導、國內外同行和朋友表示衷心的感謝并致以美好的祝愿，讓我們加強交流與合作，攜手奮進，共創光輝燦爛的明天！
Chengdu Yunke Pharmaceutical Co.,Ltd.(CYPC), reorganized from the Chengdu Isotope Application Institute of the Nuclear Power Institute of China (NPIC). CYPC is a high-tech innovational enterprise which majors in the researching the drug of radionuclidic therapy, and brings along other diagnostic nuclear medicine and therapeutic nuclear medicine. Currently, the CYPC is the third in vivo radiopharmaceuticals supplier.
We will continuously enhance our comprehensive scientific research capabilities and technical level, cultivate key competitive ability, promote the innovation in science and technology, management, system organization and operation mechanism and develop the culture having special characteristics of CYPC, accept the challenges with a flourishing attitude, march towards an international first class institute and bravely scale the height and create resplendence again for the development of nuclear physic career.
On behalf of staff of CYPC,I would like to extend our cordial thanks and nice greetings to the leaders of different ranks and the colleagues and friends home and abroad who have given concerns and supports to our work. Let’s strengthen the exchanges and cooperation, create a brilliant future together.
